Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Stopped early · Phase 1/Phase 2
Conditions studied: Macular Degeneration
In brief
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate, randomized, masked phase during which eligible patients will be randomized to the NT-503-3 group or the control group. Clinical Hypotheses: * NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD * NT-503-3 ECT has an acceptable safety profile
Key facts
- Study ID
- NCT02228304
- Run by
- Neurotech Pharmaceuticals
- People needed
- 42
- Starts
- 2014-09-01
- Expected to finish
- 2016-04-01
- Last updated by the study team
- 2022-07-18
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Associated Retina Consultants, Ltd. — Phoenix, Arizona, United States
- Retina-Vitreous Associates Medical Group — Beverly Hills, California, United States
- University of California, Irvine, The Gavin Herbert Eye Institute — Irvine, California, United States
- Jacobs Retina Center at UCSD — La Jolla, California, United States
- Colorado Retina Associates — Golden, Colorado, United States
- Retina Health Center — Fort Myers, Florida, United States
- National Ophthalmic Research Institute — Fort Myers, Florida, United States
- Center for Retina and Macular Disease — Winter Haven, Florida, United States
- Southeast Retina Center, PC — Augusta, Georgia, United States
- Georgina Retina, P.C. — Marietta, Georgia, United States
- Illinois Retina Associates, S.C. — Joliet, Illinois, United States
- Illinois Retina Associates — Oak Park, Illinois, United States
- Retina Associates of Kentucky — Lexington, Kentucky, United States
- The Retina Group of Washington — Chevy Chase, Maryland, United States
- Cumberland Valley Retina Consultants, PC — Hagerstown, Maryland, United States
- Ophthalmic Consultants of Boston — Boston, Massachusetts, United States
- University of Michigan, Kellogg Eye Center — Ann Arbor, Michigan, United States
- William Beaumont Hospital-Ophthalmology Research — Royal Oak, Michigan, United States
- Lifelong Vision Foundation — Chesterfield, Missouri, United States
- Sierra Eye Associates — Reno, Nevada, United States
- Retina Center of New Jersey, LLC — Bloomfield, New Jersey, United States
- NJ Retina — New Brunswick, New Jersey, United States
- Western Carolina Retinal Associates — Asheville, North Carolina, United States
- Wake Forest Baptist Health Eye Center — Winston-Salem, North Carolina, United States
- Cleveland Clinic — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.